DE602005008471D1 - Aryloxyethylaminderivate mit einer kombination ausonin-wiederaufnahmehemmung - Google Patents

Aryloxyethylaminderivate mit einer kombination ausonin-wiederaufnahmehemmung

Info

Publication number
DE602005008471D1
DE602005008471D1 DE602005008471T DE602005008471T DE602005008471D1 DE 602005008471 D1 DE602005008471 D1 DE 602005008471D1 DE 602005008471 T DE602005008471 T DE 602005008471T DE 602005008471 T DE602005008471 T DE 602005008471T DE 602005008471 D1 DE602005008471 D1 DE 602005008471D1
Authority
DE
Germany
Prior art keywords
ausonin
combination
derivatives
recovery inhibition
aryloxyethylamine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE602005008471T
Other languages
German (de)
English (en)
Inventor
Roelof W Feenstra
Axel Stoit
Jan-Willem Terpstra
Maria L Pras-Raves
Andrew C Mccreary
Vliet Bernard J Van
Mayke B Hesselink
Cornelis G Kruse
Scharrenburg Gustaaf J M Van
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abbott Healthcare Products BV
Original Assignee
Solvay Pharmaceuticals BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Solvay Pharmaceuticals BV filed Critical Solvay Pharmaceuticals BV
Publication of DE602005008471D1 publication Critical patent/DE602005008471D1/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/58—Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Fats And Perfumes (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DE602005008471T 2004-12-08 2005-12-06 Aryloxyethylaminderivate mit einer kombination ausonin-wiederaufnahmehemmung Expired - Fee Related DE602005008471D1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US63407404P 2004-12-08 2004-12-08
EP04106394 2004-12-08
PCT/EP2005/056505 WO2006061376A1 (en) 2004-12-08 2005-12-06 Aryloxyethylamine derivatives with a combination of partial d0pamine-d2 receptor agonism and serotonin reuptake inhibition

Publications (1)

Publication Number Publication Date
DE602005008471D1 true DE602005008471D1 (de) 2008-09-04

Family

ID=35744728

Family Applications (2)

Application Number Title Priority Date Filing Date
DE602005008471T Expired - Fee Related DE602005008471D1 (de) 2004-12-08 2005-12-06 Aryloxyethylaminderivate mit einer kombination ausonin-wiederaufnahmehemmung
DE602005010902T Expired - Fee Related DE602005010902D1 (de) 2004-12-08 2005-12-06 Phenylpiperazin-derivate mit einer kombination aus teilweisem dopamin-d2-rezeptor-agonismus und serotonin-wiederaufnahmehemmung

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE602005010902T Expired - Fee Related DE602005010902D1 (de) 2004-12-08 2005-12-06 Phenylpiperazin-derivate mit einer kombination aus teilweisem dopamin-d2-rezeptor-agonismus und serotonin-wiederaufnahmehemmung

Country Status (18)

Country Link
EP (4) EP1824479B1 (https=)
JP (4) JP2008523031A (https=)
KR (4) KR20070085988A (https=)
AT (2) ATE413173T1 (https=)
AU (4) AU2005313311A1 (https=)
BR (1) BRPI0518613A2 (https=)
CA (4) CA2587559A1 (https=)
DE (2) DE602005008471D1 (https=)
DK (2) DK1827427T3 (https=)
ES (2) ES2311245T3 (https=)
HR (2) HRP20080538T3 (https=)
IL (4) IL183061A0 (https=)
NO (4) NO20072974L (https=)
PL (2) PL1824479T3 (https=)
PT (2) PT1824479E (https=)
RU (4) RU2007125659A (https=)
SI (2) SI1824479T1 (https=)
WO (4) WO2006061376A1 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009525304A (ja) * 2006-01-30 2009-07-09 シュペーデル・エクスペリメンタ・アーゲー α，β−不飽和化合物からのアルコールの立体選択的製造方法
US8063062B2 (en) 2006-12-20 2011-11-22 Solvay Pharmaceuticals B.V. Compounds with a combination of cannabinoid-CB1 antagonism and acetylcholinesterase inhibition
EP2111394A1 (en) * 2007-01-10 2009-10-28 Solvay Pharmaceuticals B.V. Compounds with a combination of cannabinoid-cb1 antagonism and serotonin reuptake inhibition
US8138174B2 (en) 2007-01-10 2012-03-20 Solvay Pharmaceuticals B.V. Compounds with a combination of cannabinoid CB1 antagonism and serotonin reuptake inhibition
RS52518B (sr) * 2007-04-23 2013-04-30 Janssen Pharmaceutica N.V. Derivati 4-alkoksipiridazina kao brzo disocirajući dopamin 2 receptorski antagonisti
MX2009011416A (es) * 2007-04-23 2009-11-05 Janssen Pharmaceutica Nv Tia(di)azoles como antagonistas del receptor de dopamina 2 de disociacion rapida.
US20100137368A1 (en) * 2007-04-23 2010-06-03 Janssen Pharmaceutica N.V. Pyridine derivatives as fast dissociating dopamine 2 receptor antagonists
CN103360342B (zh) * 2012-04-09 2015-12-16 江苏恩华药业股份有限公司 3-氰基苯胺烷基芳基哌嗪衍生物及在制备药物中的应用
CN103570698B (zh) * 2012-08-01 2016-08-03 江苏恩华药业股份有限公司 用于制备维拉佐酮的化合物及其中间体和应用
ITMI20130392A1 (it) * 2013-03-15 2014-09-16 Dipharma Francis Srl Sintesi di un inibitore della ricaptazione della serotonina
WO2014203217A1 (en) 2013-06-21 2014-12-24 Lupin Limited Substituted heterocyclic compounds as crac modulators
WO2014207648A1 (en) 2013-06-24 2014-12-31 Lupin Limited Chromane and chromene derivatives and their use as crac modulators
WO2015014256A1 (en) 2013-07-29 2015-02-05 Sunshine Lake Pharma Co., Ltd. Substituted heteroaryl compounds and methods of use thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2692264B1 (fr) * 1992-06-12 1994-08-05 Adir Nouvelles piperazines 1,4-disubstituees, leur procede de preparation et les compositions pharmaceutiques les contenant.
EP0900792B1 (en) * 1997-09-02 2003-10-29 Duphar International Research B.V Piperazine and piperidine derivatives as 5-HT1A and dopamine D2-receptor (ant)agonists
JP2002510675A (ja) * 1998-04-08 2002-04-09 アメリカン・ホーム・プロダクツ・コーポレイション うつ病治療用のｎ−アリールオキシエチル−インドリル−アルキルアミン（５−ｈｔ１ａ受容体活性薬）
HUP0101475A3 (en) * 1998-06-19 2003-01-28 Lundbeck & Co As H 4,5,6 and 7-indole and indoline derivatives, their preparation and use
AR022303A1 (es) * 1999-01-22 2002-09-04 Lundbeck & Co As H Derivados de piperidina, tetrahidropiridina y piperazina, su preparacion y utilizacion
WO2001014330A2 (en) * 1999-08-23 2001-03-01 Solvay Pharmaceuticals B.V. Phenylpiperazines as serotonin reuptake inhibitors
BR0317126A (pt) * 2002-12-10 2005-10-25 Merck Patent Gmbh Derivados de indol e o uso dos mesmos como ligantes de 5-ht

Also Published As

Publication number Publication date
WO2006061378A1 (en) 2006-06-15
EP1827427A1 (en) 2007-09-05
NO20072974L (no) 2007-08-23
JP2008523029A (ja) 2008-07-03
SI1827427T1 (sl) 2008-12-31
KR20070085916A (ko) 2007-08-27
RU2007125658A (ru) 2009-01-20
RU2007125661A (ru) 2009-01-20
CA2587202A1 (en) 2006-06-15
BRPI0518613A2 (pt) 2008-11-25
AU2005313391A1 (en) 2006-06-15
ES2311245T3 (es) 2009-02-01
EP1824480A1 (en) 2007-08-29
PT1827427E (pt) 2008-11-03
CA2587357A1 (en) 2006-06-15
HRP20080538T3 (en) 2008-12-31
AU2005313390A1 (en) 2006-06-15
IL183064A0 (en) 2007-09-20
JP2008523031A (ja) 2008-07-03
ATE413173T1 (de) 2008-11-15
DK1827427T3 (da) 2008-11-24
KR20070085988A (ko) 2007-08-27
EP1824479B1 (en) 2008-11-05
NO20072981L (no) 2007-09-05
IL183061A0 (en) 2007-09-20
JP2008523030A (ja) 2008-07-03
DE602005010902D1 (de) 2008-12-18
HRP20090015T3 (en) 2009-02-28
DK1824479T3 (da) 2009-03-09
IL183062A0 (en) 2007-09-20
CA2587559A1 (en) 2006-06-15
RU2007125659A (ru) 2009-01-20
PL1827427T3 (pl) 2009-01-30
RU2007125660A (ru) 2009-01-20
ATE401883T1 (de) 2008-08-15
PL1824479T3 (pl) 2009-04-30
EP1827427B1 (en) 2008-07-23
PT1824479E (pt) 2009-01-30
WO2006061376A1 (en) 2006-06-15
NO20072969L (no) 2007-08-31
JP2008537725A (ja) 2008-09-25
WO2006061379A1 (en) 2006-06-15
AU2005313312A1 (en) 2006-06-15
EP1824479A1 (en) 2007-08-29
AU2005313311A1 (en) 2006-06-15
KR20070085975A (ko) 2007-08-27
CA2587381A1 (en) 2006-06-15
NO20072977L (no) 2007-09-05
EP1827426A1 (en) 2007-09-05
IL183063A0 (en) 2007-09-20
WO2006061377A1 (en) 2006-06-15
SI1824479T1 (sl) 2009-04-30
KR20070085959A (ko) 2007-08-27
ES2317335T3 (es) 2009-04-16

Similar Documents

Publication Publication Date Title
IL183064A0 (en) Phenylpiperazine derivatives with a combination of partial dopamine-d2 receptor agonism and serotonin reuptake inhibition
EA200601686A1 (ru) Замещенные производные морфолина и тиоморфолина
BRPI0507373A (pt) compostos e método de uso
BRPI0520870B8 (pt) compostos intermediários para a preparação de alfa-mercaptoacetanilidas de s-triazolila
EA200702670A1 (ru) Препарат тиенопиридинового ингибитора агрегации тромбоцитов
DK1881967T3 (da) Substituerede benzo (D) isoaxol-3-yl-amin-forbindelser som analgetika
CY1111733T1 (el) Παραγωγα 2-(1η-ινδολυλοσουλφανυλ)-βενζυλαμινης ως ssri
CR11463A (es) Compuestos de piridilmetil-sulfonamida
MX2009003713A (es) Inhibidor de progresion de enfermedad de alzheimer que contiene un compuesto heterociclico con estructura especifica.
BRPI0406704A (pt) Antagonistas de 5ht~7~ e agonistas inversos
BR0208812A (pt) Derivados fenil heterociclil éter como inibidores de recaptação de serotonina
EA200801366A1 (ru) Производные 3,6-дигидро-2-оксо-6н-1,3,4-тиадиазина
EA201290513A1 (ru) Новые производные (гетероциклотетрагидропиридин)-(пиперазинил)-1-алканона и (гетероциклодигидропирролидин)-(пиперазинил)-1-алканона и их применение в качестве ингибиторов р75
TW200633987A (en) Phenylpiperazines with a combination of affinity for dopamine-D2 receptors and serotonin reuptake sites
TW200634009A (en) Phenylpiperazine derivatives with a combination of partial dopamine-D2 receptor agonism and serotonin reuptake inhibition
TW200631952A (en) Benzdioxan piperazine derivatives with a combination of affinity for dopamine-D2 receptors and serotonin reuptake sites
EA200500237A1 (ru) Новый способ синтеза соединений 1,3-дигидро-2h-3-бензазепин-2-она и применение при синтезе ивабрадина и его солей присоединения с фармацевтически приемлемой кислотой
TW200801011A (en) New compounds II
EA200900982A1 (ru) Новый способ синтеза прамипексола и его фармацевтически приемлемых солей
CY1106649T1 (el) Νεα 1-μεθοξυ-2-φαινυλ-αιθενια χρησιμα δια την παρασκευην 5-καρβοξαλδεϋδο-2,3-διϋδροβενζοξεπινων
ATE522530T1 (de) 2-piperazin-1-yl-3h-imidazoä4,5-bü- pyridinderivate
MX2007015807A (es) Metodos de obtencion de fluorobencenamidas anticonvulsionantes.
NO20073390L (no) Fenylpiperaziner med en kombinasjon av affinitet for dopamin-D2-reseptorer og serotoningjenopptaksseter

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee